Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison

International Journal of Cancer

Volumn 138, Issue 6, 2016, Pages 1545-1553

  Firwana, Belal ^a,b   Sonbol, Mohamad Bassam ^c   Diab, Maria ^d   Raza, Shahzad ^b,e   Hasan, Rim ^f   Yousef, Ibrahim ^g   Zarzour, Ahmad ^h   Garipalli, Archana ^b   Doll, Donald ^b   Murad, M Hassan ⁱ   Al Kali, Aref ⁱ  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Department of Medicine   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g INDIANA UNIVERSITY   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

BCR ABL; chronic myelogenous leukemia; dasatinib; hematologic neoplasms; imatinib; nilotinib; tyrosine kinase inhibitor

Indexed keywords

BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; FOLLOW UP; HUMAN; MAJOR MOLECULAR RESPONSE; META ANALYSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; FEMALE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84954369684     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29889     Document Type: Article

References (47)

1. Siegel R, Ma J, Zou Z, et al., Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Ferdinand R, Mitchell SA, Batson S, et al., Treatments for chronic myeloid leukemia: a qualitative systematic review. J Blood Med 2012; 3: 51-76.
3. Jabbour E, Lipton JH., A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Clin Lymphoma Myeloma Leukemia 2013; 13: 646-56.
4. Mughal A, Aslam HM, Khan AM, et al., Bcr-Abl tyrosine kinase inhibitors-current status. Infect Agents Cancer 2013; 8: 23.
5. Bonifazi F, de Vivo A, Rosti G, et al., Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074-81.
6. Kantarjian HM, O'Brien S, Cortes JE, et al., Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033-41.
7. Roy L, Guilhot J, Krahnke T, et al., Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108: 1478-84.
8. Marfe G, Di Stefano C., Bypass mechanisms of resistance to tyrosine kinase inhibition in chronic myelogenous leukaemia. Curr Drug Discov Technol 2014; 11: 145-53.
9. Baccarani M, Castagnetti F, Gugliotta G, et al., Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis 2014; 6: e2014005.
10. Higgins JP, Green S., Cochrane handbook for systematic reviews of interventions version 5.1.0: The Cochrane Collaboration, updated March 2011.
11. Liberati A, Altman DG, Tetzlaff J, et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-e34.
12. Higgins JP, Altman DG, Gotzsche PC, et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
13. DerSimonian R, Kacker R., Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28: 105-14.
14. Higgins JP, Thompson SG, Deeks JJ, et al., Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
15. Lu G, Ades AE., Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-24.
16. Dias S, Welton NJ, Sutton AJ, et al., NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials, vol. June 2012.
17. Jabbour E, Kantarjian HM, Saglio G, et al., Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123: 494-500.
18. Cortes J, Hochhaus A, Kim DW, et al., Four-year follow-up of patients with newly diagnosed chronic myeloid leukemia in chronic phase receiving dasatinib or imatinib: efficacy based on early response. Blood (ASH Annual Meeting Abstracts) 2013; 121:Abstract 653.
19. Cortes J, Saglio G, Baccarani M, et al., Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood (ASH Annual Meeting Abstracts) 2014; 124:Abstract 152.
20. Kantarjian HM, Shah NP, Cortes JE, et al., Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123-9.
21. Kantarjian H, Shah NP, Hochhaus A, et al., Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-70.
22. Shah NP, Kantarjian H, Hochhaus A, et al., Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up. Blood (ASH Annual Meeting Abstracts) 2010; 116:Abstract 206.
23. Larson RA, Hochhaus A, Hughes TP, et al., Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197-203.
24. Larson RA, Kim DW, Jootar S, et al., ENESTnd 5-year (y) update: long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM). J Clin Oncol (ASCO Annual Meeting Abstracts) 2014; 32:Abstract 7073.
25. Kantarjian HM, Hochhaus A, Saglio G, et al., Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841-51.
26. Saglio G, Kim DW, Issaragrisil S, et al., Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-9.
27. Hughes TP, Hochhaus A, Saglio G, et al., ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Blood (ASH Annual Meeting Abstracts) 2010; 116:Abstract 207.
28. Cortes JE, Kim DW, Kantarjian HM, et al., Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30: 3486-92.
29. Cortes JE, Maru A, De Souza CA, et al., Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia-BELA trial: 24-month follow-up. Blood (ASH Annual Meeting Abstracts) 2011; 118:Abstract 455.
30. Gambacorti-Passerini C, Cortes JE, Kim DW, et al., Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up. J Clin Oncol (ASCO Annual Meeting Abstracts) 2011; 29:Abstract 6509.
31. Gambacorti-Passerini C, Kim DW, Kantarjian HM, et al., An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2010; 116:Abstract 208.
32. Lipton J, Chuah C, Guerci-Bresler A, et al., Epic: a phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML). Blood (ASH Annual Meeting Abstracts) 2014; 124:Abstract 152.
33. Lipton J, Chuah C, Guerci-Bresler A, et al., EPIC: a phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML. J Clin Oncol (ASCO Annual Meeting Abstracts) 2014; 32:Abstract 7023.
34. Radich JP, Kopecky KJ, Kamel-Reid S, et al., A randomized phase ii trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 intergroup trial. Blood (ASH Annual Meeting Abstracts) 2010; 116:Abstract 6.
35. Radich JP, Kopecky KJ, Appelbaum FR, et al., A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012; 120: 3898-905.
36. Zhou L, Wang JX, Huang XJ, et al., [Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2013; 34: 93-7.
37. Cortes JE, Kim DW, Pinilla-Ibarz J, et al., A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783-96.
38. Signorovitch J, Ayyagari R, Reichmann WM, et al., Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Treat Rev 2014; 40: 285-92.
39. Gambacorti-Passerini C, Cortes JE, Lipton JH, et al., Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014; 89: 947-53.
40. Iclusig (Ponatinib) [product information]. Cambridge, MA: ARIAD Pharmaceuticals, Inc, 2012.
41. Porkka K, Koskenvesa P, Lundan T, et al., Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008; 112: 1005-12.
42. O'Hare T, Eide CA, Deininger MW., Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242-9.
43. Guilhot F, Roy L, Tomowiak C., Current treatment strategies in chronic myeloid leukemia. Curr Opin Hematol 2012; 19: 102-9.
44. Baccarani M, Deininger MW, Rosti G, et al., European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-84.
45. Hughes TP, Hochhaus A, Branford S, et al., Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 116: 3758-65.
46. Branford S, Fletcher L, Cross NC, et al., Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330-8.
47. Jabbour E, Kantarjian H, Cortes J., Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leukemia 2015; 15: 323-34.